Non-surgical treatment of hepatocellular carcinoma

doi:10.3760/cma.j.issn.1673-422X.2014.12.015

Abstract

Abstract: Treatment strategies of advanced hepatocellular carcinoma reduce pain, improve quality of life and prolong survival. The latest developments at home and abroad focus on a variety of topical treatments (endovascular treatment, a variety of ablation therapy, radiation therapy) combined with each other and also combined with targeted therapy. In addition, systemic chemotherapy, biological targeting therapy and traditional Chinese medicine have achieved some new progressions.

Key words: Carcinoma, hepatocellular, Catheter ablation, Radiotherapy, Drug therapy, Targeted therapy

LU Guang-Ping. Non-surgical treatment of hepatocellular carcinoma[J]. Journal of International Oncology, 2014, 41(12): 925-929.

References

［1］ Nordenstedt H, White DL, ElSerag HB. The changing pattern of epidemiology in hepatocellular carcinoma［J］. Dig Liver Dis, 2010, 42(suppl 3): S206S214. ［2］ European association for the study of the liver; European organisation for research and treatment of cancer. EASLEORTC clinical practice guidelines: management of hepatocellular carcinoma［J］. J Hepatol, 2012, 56(4): 908943. ［3］ Mancuso A. Management of hepatocellular carcinoma: enlightening the gray zones［J］. World J Hepatol, 2013, 5(6):302310. ［4］ Pinter M, Hucke F, Graziadei I, et al. Advancedstage hepatocellular carcinoma: transarterial chemoembolization versus sorafenib［J］. Radiology, 2012, 263(2):590599. ［5］ Choi J, Shim JH, Shin YM, et al. Clinical significance of the best response during repeated transarterial chemoembolization in the treatment of hepatocellular carcinoma［J］. J Hepatol, 2014, 60(6): 12121218. ［6］ Sergio A, Cristofori C, Cardin R, et al. Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): the role of angiogenesis and invasiveness［J］. Am J Gastroenterol, 2008,103(4):914921. ［7］ Kumamoto T, Tanaka K, Matsuo K, et al. Adjuvant hepatic arterial infusion chemotherapy with 5Fluorouracil and interferon after curative resection of hepatocellular carcinoma: a preliminary report［J］. Anticancer Res, 2013, 33(12):55855590. ［8］ Honda Y, Kimura T, Aikata H, et al. Stereotactic body radiation therapy combined with transcatheter arterial chemoembolization for small hepatocellular carcinoma［J］. J Gastroenterol Hepatol, 2013, 28(3): 530536. ［9］ Jiang G, Xu X, Ren S, et al. Combining transarterial chemoembolization with radiofrequency ablation for hepatocellular carcinoma［J］. Tumour Biol, 2014, 35(4):34053408. ［10］ Kane RC, Farrell AT, Madabushi R, et al. Sorafenib for the treatment of unresectable hepatocellular carcinoma［J］. Oncologist, 2009, 14(1):95100. ［11］ Kudo M, Imanaka K, Chida N, et al. Phase Ⅲ study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma［J］. Eur J Cancer, 2011, 47(14):21172127. ［12］ Shiina S, Tateishi R, Imamura M, et al. Percutaneous ethanol injection for hepatocellular carcinoma: 20year outcome and prognostic factors［J］. Liver Int, 2012, 32(9):14341442. ［13］ Feng K, Ma KS. Value of radiofrequency ablation in the treatment of hepatocellular carcinoma［J］. World J Gastroenterol， 2014, 20(20):59875998. ［14］ Liu J, Qian LX. Therapeutic efficacy comparison of radiofrequency ablation in hepatocellular carcinoma and metastatic liver cancer［J］. Exp Ther Med, 2014, 7(4):897900. ［15］ Huang S, Yu J, Liang P, et al. Percutaneous microwave ablation for hepatocellular carcinoma adjacent to large vessels: a longterm followup［J］. Eur J Radiol, 2014, 83(3):552558. ［16］ Ong SL, Gravante G, Metcalfe MS, et al. Efficacy and safety of microwave ablation for primary and secondary liver malignancies: a systematic review［J］. Eur J Gastroenterol Hepatol, 2009, 21(6):599605. ［17］ Zhang ZM, Guo JX, Zhang ZC, et al. Therapeutic options for intermediateadvanced hepatocellular carcinoma［J］. World J Gastroenterol, 2011, 17(13):16851689. ［18］ Li Z, Zhang C, Lou C, et al. Comparison of percutaneous cryosurgery and surgical resection for the treatment of small hepatocellular carcinoma［J］. Oncol Lett, 2013, 6(1):239245. ［19］ Shen HP, Gong JP, Zuo GQ. Role of highintensity focused ultrasound in treatment of hepatocellular carcinoma［J］. Am Surg, 2011, 77(11):14961501. ［20］ Cheung TT, Fan ST, Chu FS, et al. Survival analysis of highintensity focused ultrasound ablation in patients with small hepatocellular carcinoma［J］. HPB(Oxford), 2013, 15(8):567573. ［21］ Sanuki N, Takeda A, Mizuno T, et al. Tumor response on CT following hypofractionated stereotactic ablative body radiotherapy for small hypervascular hepatocellular carcinoma with cirrhosis［J］. AJR Am J Roentgenol, 2013, 201(6): W812820. ［22］ Qin S, Bai Y, Lim HY, et al. Randomized, multicenter, openlabel study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia［J］. J Clin Oncol, 2013, 31（28）:35013508. ［23］ Yoon EL, Yeon JE, Lee HJ, et al. Systemic cytotoxic chemotherapy of patients with advanced hepatocellular carcinoma in the era of sorafenib nonavailability［J］. Clin Gastroenterol, 2014, 48(3):e2229. ［24］ Shao YY, Lin ZZ, Hsu C, et al. Efficacy, safety, and potential biomarkers of thalidomide plus metronomic chemotherapy for advanced hepatocellular carcinoma［J］. Oncology, 2012, 82(1):5966. ［25］ Huang TS, Shyu YC, Chen HY, et al. A systematic review and metaanalysis of adjuvant interferon therapy after curative treatment for patients with viral hepatitisrelated hepatocellular carcinoma［J］. J Viral Hepat, 2013, 20(10):729743. ［26］ Pan CC, Huang ZL, Li W, et al. Serum alphafetoprotein measurement in predicting clinical outcome related to autologous cytokineinduced killer cells in patients with hepatocellular carcinoma undergone minimally invasive therapy［J］. Chin J Cancer, 2010, 29(6): 596602. ［27］ D′Anzeo M, Faloppi L, Scartozzi M, et al. The role of MicroRNAs in Hepatocellular Carcinoma: From Molecular Biology to Treatment. Molecules［J］. 2014, 19(5):63936406. ［28］ Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma［J］. N Engl J Med, 2008, 359(4):378390. ［29］ Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the AsiaPacific region with advanced hepatocellular carcinoma: a phase III randomised, doubleblind, placebocontrolled trial［J］. Lancet Oncol, 2009, 10(1):2534. ［30］ Hu H, Duan Z, Long X, et al. Sorafenib combined with transarterial chemoembolization versus transarterial chemoembolization alone for advancedstage hepatocellular carcinoma: a propensity score matching study［J］. PLoS One, 2014, 9(5):e96620. ［31］ Chan SL, Yeo W. Development of systemic therapy for hepatocellular carcinoma at 2013: updates and insights［J］. World J Gastroenterol, 2014, 20(12):31353145. ［32］ Cheung F, Wang X, Wang N, et al. Chinese medicines as an adjuvant therapy for unresectable hepatocellular carcinoma during transarterial chemoembolization: a metaanalysis of randomized controlled trials［J］. Evid Based Complement Alternat Med, 2013,2013: 487919. ［33］ Ng L, TungPing Poon R, Yau S, et al. Suppression of actopaxin impairs hepatocellular carcinoma metastasis through modulation of cell migration and invasion［J］. Hepatology, 2013, 58(2):667679.

[1]	Qian Xiaotao, Shi Ziyi, Hu Ge, Wu Xiaowei. Efficacy of consolidation chemotherapy after radical radiotherapy and chemotherapy for stage Ⅲ-ⅣA esophageal squamous cell carcinoma： a real-world clinical study [J]. Journal of International Oncology, 2024, 51(6): 326-331.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun. Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer [J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Wang Ying, Liu Nan, Guo Bing. Advances of antibody-drug conjugate in the therapy of metastatic breast cancer [J]. Journal of International Oncology, 2024, 51(6): 364-369.
[4]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu. Research progress on intestinal flora and non-surgical treatment of the colorectal cancer [J]. Journal of International Oncology, 2024, 51(6): 376-381.
[5]	Wang Peixin, Zhao Jun, Xu Shihong, Jiang Zhaoyang, Wang Xiaoqiang, Yang Hongjuan. Progress of ferroptosis-related mechanisms in osteosarcoma [J]. Journal of International Oncology, 2024, 51(5): 308-311.
[6]	Yang Zhi, Lu Yiqiao, Gu Huayan, Ding Jialing, Guo Guilong. Research progress of tumor microenvironment mediated drug resistance in targeted therapy of breast cancer [J]. Journal of International Oncology, 2024, 51(4): 235-238.
[7]	Qian Xiaotao, Shi Ziyi, Hu Ge. A real-world clinical study of immunocheckpoint inhibitor maintenance therapy after radical radiotherapy and chemotherapy in stage Ⅲ-ⅣA esophageal squamous cell carcinoma [J]. Journal of International Oncology, 2024, 51(3): 151-156.
[8]	Li Shuyue, Ma Chenying, Zhou Juying, Xu Xiaoting, Qin Songbing. Progress of radiotherapy in oligometastatic non-small cell lung cancer [J]. Journal of International Oncology, 2024, 51(3): 170-174.
[9]	Yue Hongyun, Zhang Baihong. Differentiation therapies in human cancers [J]. Journal of International Oncology, 2024, 51(2): 109-113.
[10]	Jin Xudong, Chen Zhongjian, Mao Weimin. Research progress on the role of MTAP in malignant mesothelioma [J]. Journal of International Oncology, 2024, 51(2): 99-104.
[11]	Gao Xinyu, Li Zhenjiang, Sun Hongfu, Han Dan, Zhao Qian, Liu Chengxin, Huang Wei. Clinical application of MR-guided radiotherapy based on MR-linac in esophageal cancer patients [J]. Journal of International Oncology, 2024, 51(1): 37-42.
[12]	Cui Tenglu, Lyu lu, Sun Pengfei. Application of radiotherapy combined with immunotherapy in the treatment of head and neck squamous cell carcinoma [J]. Journal of International Oncology, 2023, 50(9): 548-552.
[13]	Huang Hui, Ding Jianghua. Advances in targeting FGFR2 for treatment of advanced cholangiocarcinoma [J]. Journal of International Oncology, 2023, 50(9): 569-573.
[14]	Wang Ting, Li Wenqian, Xie Youbang. Correlation between hypoxia and the oxygen sensing pathway in acute myeloid leukemia cells [J]. Journal of International Oncology, 2023, 50(8): 503-507.
[15]	Li Chenxi, Zhao Hongwei. Prognosis and influencing factors of platinum sensitive recurrent ovarian cancer treated by secondary cytoreduction surgery in patients with unsatisfactory primary cytoreduction surgery [J]. Journal of International Oncology, 2023, 50(6): 342-347.